Want to see IN:KRSNAA full AI Analyst Report?
Krsnaa Diagnostics Limited (KRSNAA) AI Stock Analysis
Krsnaa Diagnostics Limited
(NSE:KRSNAA)
Strong balance sheet and revenue growth in financial performance are the primary positives driving the score, tempered by negative free cash flow and mixed technical signals with short-term support but long-term caution; fair valuation adds stability.
Krsnaa Diagnostics Limited (KRSNAA) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 16.14B
- Dividend Yield
- 0.40%
- Average Volume (3M)
- 7,796
- Price to Earnings (P/E)
- 16.8
- Beta (1Y)
- 0.99
- Revenue Growth
- 10.19%
- EPS Growth
- 20.99%
- Country
- India
- Employees
- 3,296
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Krsnaa Diagnostics Limited Business Overview & Revenue Model
Company Description
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers mammography, stress tests, dual-energy X-ray absorptiometry scans, bone mineral density tests, computed tomography scans, and magnetic resonance imaging services, as well as...
How the Company Makes Money
Krsnaa Diagnostics makes money primarily by providing diagnostic services and charging for tests and imaging procedures. Its revenue model is largely service-led and includes: (1) Pathology (clinical laboratory) revenue: fees earned from processing a...
Krsnaa Diagnostics Limited Financial Statement Overview
Summary
Strong balance sheet with equity growth to 9.80 billion and low debt-to-equity of 0.1 supports outlook; revenue expansion to 7.72 billion aids score, offset by negative free cash flow from high capex.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.15B | 7.73B | 7.17B | 6.20B | 4.87B | 4.55B |
| Gross Profit | 3.68B | 3.01B | 5.48B | 2.05B | 4.13B | 3.95B |
| EBITDA | 2.26B | 2.55B | 2.16B | 1.61B | 1.42B | 1.46B |
| Net Income | 974.60M | 1.01B | 776.08M | 568.37M | 621.11M | 683.88M |
Balance Sheet | ||||||
| Total Assets | 0 | 18.24B | 12.82B | 11.72B | 9.10B | 8.76B |
| Cash, Cash Equivalents and Short-Term Investments | 3.61B | 3.61B | 684.36M | 535.45M | 1.09B | 2.42B |
| Total Debt | 0 | 5.34B | 2.04B | 1.60B | 324.81M | 409.92M |
| Total Liabilities | -9.80B | 8.43B | 3.99B | 3.62B | 1.71B | 2.07B |
| Stockholders Equity | 9.80B | 9.80B | 8.83B | 8.10B | 7.39B | 6.84B |
Cash Flow | ||||||
| Free Cash Flow | -516.97M | -942.60M | -393.00M | -1.70B | -650.59M | -37.95M |
| Operating Cash Flow | 518.74M | 1.25B | 873.27M | 243.45M | 763.01M | 1.28B |
| Investing Cash Flow | -1.04B | -4.04B | -996.09M | -1.29B | -1.09B | -2.41B |
| Financing Cash Flow | 592.91M | 3.06B | 137.53M | 841.87M | -331.45M | 1.76B |
Krsnaa Diagnostics Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KRSNAA, the sentiment is Negative. The current price of 504.10 is below the 20-day moving average (MA) of 523.39, below the 50-day MA of 540.71, and below the 200-day MA of 581.59, indicating a bearish trend. The MACD of -13.35 indicates Positive momentum. The RSI at 38.60 is Neutral, neither overbought nor oversold. The STOCH value of 34.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KRSNAA.
Krsnaa Diagnostics Limited Peers Comparison
Overall Rating
IN:LALPATHLAB74Outperform
IN:VIJAYA70.75Outperform- IN:KRSNAA70Outperform
IN:THYROCARE65Neutral
IN:SURAKSHA64.5Neutral
IN:METROPOLIS59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:LALPATHLAB | 74Outperform | INR 319.97B | 58.77 | ― | 0.84% | 14.29% | 5.55% |
| IN:VIJAYA | 71Outperform | INR 149.06B | 79.30 | ― | 0.14% | 20.18% | 24.71% |
| IN:KRSNAA | 70Outperform | INR 16.35B | 16.77 | ― | 0.40% | 10.19% | 20.99% |
| IN:THYROCARE | 65Neutral | INR 72.74B | 50.42 | ― | 2.04% | 21.99% | 12.77% |
| IN:SURAKSHA | 65Neutral | INR 16.53B | 45.98 | ― | 0.31% | 23.31% | 7.56% |
| IN:METROPOLIS | 59Neutral | INR 113.09B | 56.06 | ― | 0.37% | 21.80% | 31.84% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:KRSNAA | Krsnaa Diagnostics Limited | 504.10 | -281.30 | -35.82% | |
| IN:LALPATHLAB | Dr. Lal PathLabs Limited | 1906.30 | 296.36 | 18.41% | |
| IN:METROPOLIS | Metropolis Healthcare Ltd. | 545.15 | 46.06 | 9.23% | |
| IN:SURAKSHA | Suraksha Diagnostic Ltd. | 317.40 | 1.74 | 0.55% | |
| IN:THYROCARE | Thyrocare Technologies Ltd | 457.00 | 2.20 | 0.48% | |
| IN:VIJAYA | Vijaya Diagnostic Centre Ltd. | 1447.25 | 429.81 | 42.24% |
Krsnaa Diagnostics Limited Corporate Events
Krsnaa Diagnostics Taps AZmed’s Radiology AI to Scale X-ray Reporting
Krsnaa Diagnostics has announced a strategic collaboration with Paris-based radiology AI specialist AZmed to evaluate the latter’s AZtrauma solution, part of the Rayvolve suite, for detecting and triaging fractures, joint effusions and dislocat...
Krsnaa Diagnostics Secures Exchange Nod for Promoter-Focused Warrant Issue
Krsnaa Diagnostics Limited has received in-principle approvals from BSE and the National Stock Exchange of India to issue 1,621,000 convertible warrants on a preferential basis to its promoter and promoter group. The warrants are convertible into an...
Krsnaa Diagnostics Wins Exchange Nod for Preferential Issue of Convertible Warrants
Krsnaa Diagnostics Limited has received in-principle approvals from BSE and the National Stock Exchange of India for the issue of 1,621,000 convertible warrants to its promoter and promoter group on a preferential basis, each warrant convertible into...
Krsnaa Diagnostics Wins Shareholder Nod for Promoter-Backed Warrant Issue
Krsnaa Diagnostics Limited has secured shareholder approval to issue up to 1,621,000 warrants, convertible into equity shares of Rs 5 each, on a preferential basis to its promoter and promoter group. The approval was obtained via a postal ballot cond...
Krsnaa Diagnostics Announces Dispatch of Annual Report and AGM Notice
Krsnaa Diagnostics Limited has completed the dispatch of its Annual Report along with the notice convening its 16th Annual General Meeting to shareholders. The company has also published statutory advertisements about this completion and the AGM noti...
Krsnaa Diagnostics Clears Q1 Results, Sets AGM and Approves Promoter Warrants Issue
Krsnaa Diagnostics Limited’s board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and cleared the director’s report and accompanying annexures for the 2025-26 financial year. The...
Krsnaa Diagnostics Posts 22% Revenue Growth as Rajasthan Network Goes Live and Promoters Back Expansion
Krsnaa Diagnostics reported a 22% year-on-year rise in Q1 FY2027 revenue from operations to ₹2,355 million, driven by growth in its established business and contributions from newly commissioned projects. Like-for-like projects grew about 12%,...
Krsnaa Diagnostics Releases Investor Presentation on Q1 FY2026-27 Results
Krsnaa Diagnostics Limited has released an investor and analyst presentation detailing its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The disclosure, made under SEBI’s Listing Obligations and Di...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026